Recombinant AAT Production via Temperature Shifts and Inducible Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant human alpha 1-antitrypsin (AAT) are inefficient, resulting in low yields and substandard quality, making it difficult to meet the demand for effective treatment of AAT deficiency-related diseases, as existing technologies struggle to produce high-quality, high-yielding AAT proteins with sufficient glycosylation and bioavailability.
Innovation Solution
The development of recombinant AAT production methods using CHO cell lines optimized for high-yield productivity, involving expression vectors and transposase-mediated gene integration, which enable the production of AAT with enhanced glycosylation patterns and high purity, allowing for large-scale manufacturing and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing recombinant AAT are used, then production can proceed with existing technology, but yields are low and quality is substandard
Solution Approach 1:
The patent modifies culture temperature parameters (shifting from 37°C to lower temperatures like 30-33°C during production phase) and uses inducible expression systems to optimize both yield and quality of recombinant AAT, resolving the contradiction between productivity and manufacturing precision
Solution Approach 2:
The patent employs dynamic culture conditions including phased temperature shifts, inducible expression systems (e.g., tetracycline-regulated systems), and adaptive feeding strategies to continuously optimize AAT production, enabling the system to transition from growth phase to production phase and achieve both high yield and high quality
2Reliability
If existing production methods are used, then manufacturing can continue, but glycosylation patterns are insufficient and bioavailability is reduced
Solution Approach 1:
The patent optimizes culture conditions including temperature, pH, and nutrient composition to enhance glycosylation patterns of recombinant AAT, ensuring proper post-translational modifications that improve bioavailability while maintaining manufacturability
Solution Approach 2:
The patent uses CHO cells as an intermediary host system that naturally performs human-like glycosylation, allowing the production of recombinant AAT with appropriate glycosylation patterns and bioavailability without requiring complex additional manufacturing steps
3Quantity of substance
If plasma-derived AAT is used for treatment, then therapy can be provided, but supply is limited and costs are high
Solution Approach 1:
The patent creates recombinant copies of human AAT in CHO cells, producing identical or improved versions of the therapeutic protein that can be manufactured at scale without relying on limited plasma donations, thereby increasing supply and reducing costs
Solution Approach 2:
The patent separates AAT production from plasma collection by using cell culture systems, allowing independent optimization of production processes and enabling scalable manufacturing through bioreactor systems rather than being constrained by plasma donation rates
4Productivity
If recombinant AAT production is scaled up, then supply can increase, but maintaining high purity and quality becomes more difficult
Solution Approach 1:
The patent designs expression systems where the host cells (CHO cells) naturally perform quality control functions including proper folding, glycosylation, and quality assurance of the recombinant AAT, reducing the burden on downstream purification processes and maintaining high purity at scale
Solution Approach 2:
The patent optimizes culture parameters including temperature, pH, dissolved oxygen, and feeding strategies to maintain cell health and product quality during scale-up, ensuring consistent high-purity AAT production from laboratory to manufacturing scale
Data Source
AI summary
Embodiments of the present invention generally relate to recombinant alpha 1-antitrypsin (AAT) proteins, including variants of human AAT with individually introduced mutations, compositions containing such recombinant AAT proteins and carriers, expression plasmids or vectors and host cells that express such recombinant AAT proteins, methods of producing such recombinant AAT proteins, and methods of treating AAT deficiency-related diseases, disorders, and conditions or diseases, disorders, and conditions resulting in protease-induced tissue damage in a subject in need thereof with the recombinant AAT proteins and/or recombinant AAT protein compositions described here. The recombinant AAT proteins derived from mammalian host cells as produced by the methods described here may be produced in large quantities, without any animal components, i.e., highly pure, highly glycosylated, and may be advantageously used over plasma-derived AAT.